Browse evidence-based analysis of health-related claims and assertions
Taking a weekly exenatide shot doesn’t lower the chance of eye problems from diabetes, even if your blood sugar improves or you already had early eye issues.
Taking a weekly exenatide shot doesn’t really change how well your kidneys are working if you have type 2 diabetes — the numbers stayed about the same over time.
A weekly diabetes shot called exenatide doesn’t lower the chance of ending up in the hospital for heart failure for the first time in people with type 2 diabetes — it’s basically neutral, even though it might help if someone already has heart issues.
If you have type 2 diabetes and already have heart failure, the weekly diabetes shot exenatide might not help you live longer or keep you out of the hospital for heart problems. But if your heart is healthy, it could lower your risk of dying by 21%.
Taking a weekly diabetes shot called exenatide doesn’t stop the first heart failure hospital stay, but it does cut down on how often people end up back in the hospital for heart problems by about 18%.
Taking a weekly diabetes shot called exenatide may help lower the chance of dying or ending up in the hospital with heart failure for people with type 2 diabetes.
A weekly diabetes shot called exenatide may help people with type 2 diabetes live longer, especially if they don’t already have heart failure.
A few small studies have tested diabetes drugs like Exenatide and Dulaglutide in people with addiction, and while there’s not much data yet, it’s an area scientists are starting to explore.
People who take certain diabetes drugs like Exenatide or Dulaglutide tend to lose weight and have better blood sugar control, according to several medical studies.
Some diabetes drugs like Exenatide and Dulaglutide might help people cut down on drinking alcohol or smoking, based on several medical studies.
Even though these brain scans don't work very well in people yet, animal studies show they might one day help track brain changes in diseases like Alzheimer's.
A special kind of body scan using a radioactive tag might help scientists see how insulin-making cells change in people with diabetes or obesity, which could help in developing new treatments.
If someone has obesity, their body might have fewer GLP-1 receptors. A special scan could help doctors see if those receptors come back after treatment with certain weight-loss drugs or surgery.
A special kind of body scan might help doctors tell the difference between when insulin-making cells in the pancreas are gone versus just not working right — without needing surgery — which could help better manage diabetes.
A special kind of body scan using a tagged molecule might help doctors find tiny tumors in the pancreas that cause low blood sugar — all without surgery.
In the human heart, the GLP-1 receptor is more active than similar receptors, and one of them isn't detectable at all in a key heart chamber — suggesting the heart may respond more to GLP-1-based signals.
We know the heart has the genetic instructions for a certain protein (GLP-1R), but we can't yet tell which exact heart cells actually make it because our tools aren't sensitive enough to see it clearly.
Scientists found the genetic instructions for a certain receptor in the heart's natural pacemaker, which might mean that a hormone involved in blood sugar control could directly affect how fast your heart beats.
The gene for the GLP-1 receptor isn't found in certain heart cells, so those cells probably aren't the main places where this receptor works in the human heart when things are normal.
The heart has the same kind of genetic message for the GLP-1 receptor as the pancreas, which means the heart might respond to GLP-1 signals—even though we're not sure yet if that message actually turns into working proteins there.
Some tumors have a special marker that might let doctors see them better on scans or treat them with targeted radiation, because the marker shows up strongly on the tumor but not in healthy tissue around it.
Scientists used a labeled version of a hormone to see where it sticks in human tissues, and the pattern they found confirms it’s attaching to specific receptors linked to GLP-1 — in both healthy and tumor tissues.
GLP-1 receptors are found in small amounts in certain parts of healthy human organs like the pancreas, gut, lungs, and brain, but they’re not found at all in the liver, spleen, lymph nodes, or adrenal glands.
Some tumors have a special 'door' called GLP-1 receptors that other cancers don’t have — this might let doctors target just those tumors without affecting healthy cells.